Roche Reaffirms Commitment to Huntington's and Alzheimer's Therapies Through New RNA-Targeted Collaboration with Ionis

Under the terms of the agreement, Ionis will be responsible for advancing these two projects through preclinical studies; Roche will have full responsibility for clinical development and, if approved, global commercialization. Ionis will receive a $60 million upfront payment from Roche and is eligible for development, regulatory, and commercial milestone payments as well as tiered royalties. Dr. Brett P. Monia.